SCHEMBL10252609

SCHEMBL10252609

Cc1ccc2c(c1)nc(-c1ccncc1SC(F)(F)F)n2C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ ATM Q13315 1/20 0.39
▸ AGPAT2 O15120 1/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ TP53 P04637 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ CASP1 P29466 1/20 0.38
▸ ACSS2 Q9NR19 1/20 0.38
▸ KDM4E B2RXH2 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP11B1 P15538 2/20 0.34
▸ CYP11B2 P19099 2/20 0.34
▸ RPS6KA5 O75582 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10248994 0.89 SMN1; SMN2 (0.43) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10248979 0.89 SMN1; SMN2 (0.39) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10284936 0.88 PDE10A (0.43) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10248930 0.85 SMN1; SMN2 (0.45) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10249078 0.82 POLB (0.34) SMN1; SMN2POLBATMNPC1TP53
SCHEMBL10248957 0.82 SMN1; SMN2 (0.43) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10249072 0.82 SMN1; SMN2 (0.43) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10249110 0.81 SMN1; SMN2 (0.40) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10249295 0.81 SMN1; SMN2 (0.42) SMN1; SMN2POLBATMAGPAT2NPC1
SCHEMBL10284537 0.81 PDE10A (0.42) SMN1; SMN2POLBATMAGPAT2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461181-B2 Fused heterocyclic compound and use thereof SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2013-06-11 — — US disclosed
US-8273764-B2 Fused heterocyclic compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-09-25 — — US disclosed
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED 2012-07-12 — — US disclosed
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178779-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885
US-20120015975-A1 FUSED HETEROCYCLIC COMPOUND AND USE THEREOF C3AR1, C9, C5 SMN1; SMN2 1524/4885POLB 4724/4885ATM 4476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback